Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.964
-0.016 (-1.66%)
At close: Dec 20, 2024, 4:00 PM
0.990
+0.026 (2.74%)
After-hours: Dec 20, 2024, 7:36 PM EST
Atossa Therapeutics Employees
Atossa Therapeutics had 12 employees as of December 31, 2023. The number of employees increased by 1 or 9.09% compared to the previous year.
Employees
12
Change (1Y)
1
Growth (1Y)
9.09%
Revenue / Employee
n/a
Profits / Employee
-$2,242,583
Market Cap
121.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
American Well | 1,104 |
Enanta Pharmaceuticals | 145 |
Zomedica | 144 |
InflaRx | 62 |
Black Diamond Therapeutics | 54 |
Elutia | 54 |
Sensus Healthcare | 35 |
Galectin Therapeutics | 14 |
ATOS News
- 9 days ago - Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 10 days ago - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - GlobeNewsWire
- 11 days ago - Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 12 days ago - Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 5 weeks ago - Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - GlobeNewsWire